• Alias: KTE-C19 CAR
    • A preparation of autologous peripheral blood T-lymphocytes that have been transduced with a gamma-retroviral vector expressing a CAR consisting of an anti-CD19 scFv coupled to the costimulatory signaling domain CD28 and the zeta chain of the TCR/CD3 complex (CD3 zeta), resulting in immunostimulation.
    • FDA approved on November 8, 2017 for adults with relapsed/refractory large B-cell lymphoma such as diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, or high-grade B-cell lymphoma
    • Recommended dose: A treatment course consists of lymphodepleting chemotherapy with fludarabine and cyclophosphamide on the fifth, fourth, initiating lymphodepleting chemotherapy). Ensure tocilizumab and emergency equipment are available prior to axicabtagene ciloleucel infusion and during recovery period. Premedicate with acetaminophen 650 mg orally and diphenhydramine 12.5 mg IV or orally â™60 minutes prior to axicabtagene ciloleucel infusion. Avoid prophylactic systemic corticosteroids because they may interfere with the axicabtagene ciloleucel activity. IV: Target dose: 2 × 10
    Other topics in Targeted and Immunotherapy Agents